INLB (Item 9 Labs) Beneish M-Score: 0.00 (As of Jun. 25, 2026)


INLB Item 9 Labs Corp INLB
12 GF Score
Price $0.00
View Full Analysis

What is Item 9 Labs Beneish M-Score?

Item 9 Labs INLB -99.00% 12 Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus rates INLB with a GF Score™ of 12/100.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Item 9 Labs's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Item 9 Labs was 0.00. The lowest was 0.00. And the median was 0.00.

Item 9 Labs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Item 9 Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Item 9 Labs Beneish M-Score Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.57 -4.54 -0.10 -3.98

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.60 -3.98 -4.11 -3.97 -2.84

INLB vs NEPT, CENBF, SGBI: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Item 9 Labs Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Beneish M-Score falls into.


INLB
12GF Score
Item 9 Labs Corp INLB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Item 9 Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Item 9 Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.9805+0.528 * 0.6708+0.404 * 1.0289+0.892 * 0.8256+0.115 * 1.1237
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1726+4.679 * -0.161746-0.327 * 1.5222
=-2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $0.97 Mil.
Revenue was 5.022 + 5.663 + 5.004 + 4.001 = $19.69 Mil.
Gross Profit was 2.819 + 3.718 + 2.622 + 0.646 = $9.81 Mil.
Total Current Assets was $3.35 Mil.
Total Assets was $112.02 Mil.
Property, Plant and Equipment(Net PPE) was $24.97 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.83 Mil.
Selling, General, & Admin. Expense(SGA) was $17.91 Mil.
Total Current Liabilities was $58.81 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Net Income was -5.911 + -3.417 + -3.258 + -18.449 = $-31.04 Mil.
Non Operating Income was -0.169 + 0 + 0.003 + -11.631 = $-11.80 Mil.
Cash Flow from Operations was 0.15 + 0.303 + -1.335 + -0.238 = $-1.12 Mil.
 Total Receivables was $0.59 Mil.
Revenue was 4.931 + 6.638 + 6.186 + 6.094 = $23.85 Mil.
Gross Profit was 1.59 + 2.677 + 2.399 + 1.301 = $7.97 Mil.
Total Current Assets was $5.69 Mil.
Total Assets was $120.53 Mil.
Property, Plant and Equipment(Net PPE) was $27.31 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.27 Mil.
Selling, General, & Admin. Expense(SGA) was $18.49 Mil.
Total Current Liabilities was $39.47 Mil.
Long-Term Debt & Capital Lease Obligation was $2.21 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.968 / 19.69) / (0.592 / 23.849)
=0.049162 / 0.024823
=1.9805

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(7.967 / 23.849) / (9.805 / 19.69)
=0.33406 / 0.497969
=0.6708

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.347 + 24.968) / 112.015) / (1 - (5.692 + 27.308) / 120.528)
=0.747221 / 0.726205
=1.0289

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=19.69 / 23.849
=0.8256

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.271 / (2.271 + 27.308)) / (1.831 / (1.831 + 24.968))
=0.076777 / 0.068323
=1.1237

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.905 / 19.69) / (18.494 / 23.849)
=0.909345 / 0.775462
=1.1726

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.145 + 58.813) / 112.015) / ((2.205 + 39.47) / 120.528)
=0.52634 / 0.34577
=1.5222

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-31.035 - -11.797 - -1.12) / 112.015
=-0.161746

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Item 9 Labs has a M-score of -2.84 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Item 9 Labs (INLB) has a Beneish M-Score of 0.00 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Item 9 Labs and its competitors.
Is Item 9 Labs' Beneish M-Score too high?
Item 9 Labs' current Beneish M-Score is 0.00. Overall, Item 9 Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Item 9 Labs' Beneish M-Score compare to NEPT and CENBF?
Item 9 Labs' Beneish M-Score of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Item 9 Labs and its competitors. Item 9 Labs's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Item 9 Labs stock overvalued right now?
Item 9 Labs (INLB) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Item 9 Labs' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Item 9 Labs (INLB), the current Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Item 9 Labs Business Description

Address 2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
12GF Score

Get the complete analysis for INLB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price